Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2007

View Archived Issues

Studies of dapagliflozin, sergliflozin presented at EASD

Phase I/II studies assess ABT-751 combination therapy in non-small cell lung cancer

CADI-05 enhances chemotherapy for non-small cell lung cancer

Preclinical antitumor activity of the HDAC inhibitor panobinostat

Collaboration between SMA Foundation and BG Medicine / News in Context

CHMP recommends approval of Tasigna in CML patients nonresponsive to Glivec

NIDDK plans study of diabetes vaccine Diamyd for type 1 diabetes

FDA approves Novo Nordisk's Norditropin for children with Turner syndrome

Roche places hold on development of MAXY-alpha for hepatitis C and B

Exelixis and Bristol-Myers extend collaboration agreement for therapies targeting LXR

Patient enrollment for NeurogesX's confirmatory phase III trial of NGX-4010 completed

Efficacy of RAM-150 against multidrug-resistant pathogens

Pan-PPAR agonist PPM-204 lowers glucose and insulin in patients with type 2 diabetes

Novozymes reports on new defensin-type plectasin derivatives with in vivo antibacterial efficacy

CHMP issues positive opinion for Pegintron and Rebetol for retreating hepatitis C

Abbott and Eisai file for approval of second indication of adalimumab in Japan

Odanacatib increases bone mineral density in postmenopausal women

Preclinical models, phase I study detail activity of ACE-011

Eucreas recommended for E.U. approval in type 2 diabetes

Onconase enhances radiation responses in models of lung cancer

Adnexus Therapeutics to be acquired by Bristol-Myers Squibb

CHMP grants positive opinion to Vectibix MAA for metastatic colorectal cancer

Metabolex initiates phase II trial of MBX-8025 alone and with Lipitor

New therapeutic agents for heart failure disclosed in recent Cytokinetics patent

Novel agents for treating irritable bowel syndrome disclosed in recent Astellas patents

Novel treatment option for obesity and related disorders reported in recent Glenmark patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...